19 completed, 7 recruiting, 4 active not recruiting, 4 terminated. 39 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 39 | Completed 19, Recruiting 7, Active not recruiting 4, Terminated 4, Unknown 4, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 2, Recruiting 2, Completed 1, Unknown 1, Withdrawn 1 |
Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 470 | 2025-10-23 | 2026-06-03 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-03-16 | 2026-11-10 |
| The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, Cisplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 10 | 2024-08-13 | 2026-10-19 |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Carboplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 304 | 2024-07-19 | 2026-11-12 |
| Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Sacituzumab tirumotecan, Doxorubicin, Paclitaxel - Endometrial Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 710 | 2023-12-06 | 2026-08-28 |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence Gemcitabine, Nab paclitaxel, Cisplatin - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Gruppo Oncologico del Nord-Ovest | 300 | 2023-11-07 | 2026-09-09 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 474 | 2023-07-12 | 2026-08-17 |
| Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed - NSCLC | Phase 3 | Terminated | EQRx International, Inc. | 8 | 2022-12-14 | 2024-05-02 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer SBP-101, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Panbela Therapeutics, Inc. | 600 | 2022-08-08 | 2024-11-06 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver | Phase 2 / Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2021-11-01 | 2022-04-01 | |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) Pembrolizumab SC, Pembrolizumab IV, Paclitaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 531 | 2021-08-05 | 2026-10-07 |
| RegoNivo vs Standard of Care Chemotherapy in AGOC Regorafenib, Nivolumab, Docetaxel - Gastro-Oesophageal Cancer | Phase 3 | Completed | Australasian Gastro-Intestinal Trials Group | 462 | 2021-05-05 | 2026-06-10 |
| Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy. Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 600 | 2021-04-01 | 2021-04-08 |
| Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 120 | 2021-01-01 | 2022-06-23 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Corcept Therapeutics | 43 | 2020-06-30 | 2023-11-18 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss alpelisib, placebo, nab-paclitaxel - Triple Negative Breast Neoplasms | Phase 3 | Terminated | Novartis Pharmaceuticals | 137 | 2020-06-08 | 2026-09-10 |
| A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer Atezolizumab, Nab-Paclitaxel - Triple-Negative Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 184 | 2019-12-10 | 2025-12-26 |
| Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX - Pancreatic Cancer Non-resectable | Phase 3 | Completed | Kyntra Bio | 284 | 2019-05-10 | 2024-11-05 |
Showing 20 of 39. Sign in to see all of them.
Pancreatic Neoplasms (11) · Breast Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Adenocarcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Ductal, Breast (2) · Cholangiocarcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Site (2) · Pancreatic Diseases (2)
Celgene (4) · Merck Sharp & Dohme LLC (3) · Fondazione Michelangelo (2) · Fudan University (2) · Hoffmann-La Roche (2) · NRG Oncology (2) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · Alliance for Clinical Trials in Oncology (1) · Australasian Gastro-Intestinal Trials Group (1) · Bristol-Myers Squibb (1) · Cellectar Biosciences, Inc. (1) · Corcept Therapeutics (1) · EQRx International, Inc. (1) · First Affiliated Hospital Xi'an Jiaotong University (1)
United States (28) · Italy (18) · Spain (18) · Germany (16) · France (14) · Australia (13) · Canada (13) · Austria (12) · South Korea (11) · United Kingdom (11) · China (10) · Belgium (9) · Poland (9) · Taiwan (9) · Japan (8)
Luca Gianni, MD (2) · Alex A. Adjei, MD, PhD (1) · Arthur William Blackstock, MD (1) · Benjamin Movsas, MD (1) · Charles B Simone (1) · Daniel Von Hoff, MD (1) · Evan Hersh, MD (1) · George Blumenschein, MD (1) · Gregory A. Masters, MD (1) · Hak Choy, MD (1) · Hiroji Iwata, MD, PhD (1) · Hope S Rugo (1)
PMID 20164695, PMID 22162229, PMID 24131140, PMID 25398812, PMID 25601342, PMID 25638248, PMID 26056183, PMID 26372701, PMID 26606200, PMID 26655559, PMID 26802153, PMID 26802160, PMID 26869049, PMID 28315068, PMID 28620884, PMID 29327055, PMID 30914290, PMID 30998813, PMID 31841363, PMID 31849532, PMID 32450725, PMID 33345430, PMID 33630475, PMID 33661301, PMID 33813673, PMID 34252375, PMID 34616010, PMID 35182721, PMID 36436615, PMID 36521097, PMID 36738929, PMID 36814222, PMID 36842666, PMID 37014668, PMID 37368098, PMID 38508449, PMID 38589856, PMID 38935373, PMID 39169033, PMID 39615497, PMID 39671534, PMID 39854662, PMID 42535874, PMID 42604879
2023 (3), 2019 (2), U10CA180868 (2), U10CA180888 (2), 2014 (1), 2025 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)